Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023 - Marketscreener.com
| YPH Stock | EUR 9.61 0.11 1.16% |
Roughly 51% of Astellas Pharma's investor base is interested to short. The analysis of current outlook of investing in Astellas Pharma suggests that many traders are impartial regarding Astellas Pharma's prospects. The current market sentiment, together with Astellas Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Astellas Pharma stock news signals to limit their universe of possible portfolio assets.
Astellas Pharma stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Astellas daily returns and investor perception about the current price of Astellas Pharma as well as its diversification or hedging effects on your existing portfolios.
Astellas |
Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023 Marketscreener.com
Read at news.google.com
 |
Astellas Pharma Fundamental Analysis
We analyze Astellas Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Astellas Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Astellas Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Astellas Pharma is rated below average in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Astellas Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Astellas Pharma stock to make a market-neutral strategy. Peer analysis of Astellas Pharma could also be used in its relative valuation, which is a method of valuing Astellas Pharma by comparing valuation metrics with similar companies.
Peers
Astellas Pharma Related Equities
| AMG | Amgen | 3.46 | ||||
| YPH | Astellas Pharma | 1.16 | ||||
| 6MK | Merck | 1.15 | ||||
| YPHA | ASTELLAS PHARMA | 1.07 | ||||
| BAYN | Bayer AG | 0.97 | ||||
| IDP | Biogen | 0.36 | ||||
| RHO6 | Roche Holding | 0.51 | ||||
| CVGU | CSPC PHARMACEUTGR | 1.74 | ||||
| BAYA | Bayer Aktiengesellscha | 2.83 |
Complementary Tools for Astellas Stock analysis
When running Astellas Pharma's price analysis, check to measure Astellas Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astellas Pharma is operating at the current time. Most of Astellas Pharma's value examination focuses on studying past and present price action to predict the probability of Astellas Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astellas Pharma's price. Additionally, you may evaluate how the addition of Astellas Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |